Arrowhead Pharmaceuticals (ARWR) Other Accumulated Expenses (2012 - 2026)

Arrowhead Pharmaceuticals (ARWR) has 14 years of Other Accumulated Expenses data on file, last reported at $11.2 million in Q1 2026.

• Quarterly Other Accumulated Expenses rose 2401.12% year-over-year to $11.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $11.2 million (up 2401.12% YoY) and the FY2025 annual result came in at $10.8 million, up 2402.55% from the prior year.
• Other Accumulated Expenses grew to $11.2 million in Q1 2026, from $10.7 million in the prior quarter.
• In the past five years, Other Accumulated Expenses ranged from a high of $11.2 million in Q1 2026 to a low of $417000.0 in Q2 2024.
• A 4-year average of $3.9 million and a median of $461000.0 in 2023 frame the typical range for Other Accumulated Expenses.
• The widest YoY moves for Other Accumulated Expenses: up 2402.55% in 2025, down 21.82% in 2025.
• Tracing ARWR's Other Accumulated Expenses over 4 years: stood at $461000.0 in 2023, then retreated by 4.56% to $440000.0 in 2024, then jumped by 2326.14% to $10.7 million in 2025, then advanced by 4.96% to $11.2 million in 2026.
• The last three Other Accumulated Expenses figures came in at $11.2 million (Q1 2026), $10.7 million (Q4 2025), and $10.8 million (Q3 2025), per Business Quant data.